Exact Sciences Corp (EXAS) 24.07 $EXAS
Exact Sciences Announces Meriter-UnityPoint Health Now Offering Cologuard(R)
Business Wire - Wed Oct 29, 8:00AM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that Meriter-UnityPoint Health will now offer Cologuard(R), the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer.
EXAS: 24.07 (-0.74)
Downgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Tue Oct 28, 7:04AM CDT
Exact Sciences (NASDAQ:EXAS) was downgraded from Overweight to Equal Weight at Stephens today. The stock closed yesterday at $23.61 on volume of 2.4 million shares, below average daily volume of 2.5 million. Exact Sciences (NASDAQ:EXAS) is currently priced 20.7% above its average consensus analyst price target of $18.73. The stock should discover initial support at its 50-day moving average (MA) of $20.89 and subsequent support at its 200-day MA of $15.94.
EXAS: 24.07 (-0.74)
Exact Sciences misses 3Q profit forecasts
Automated Insights - Mon Oct 27, 6:36AM CDT
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Monday reported a third-quarter loss of $32.1 million.
EXAS: 24.07 (-0.74)
Exact Sciences Reports Third-Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 6:30AM CDT
Exact Sciences Corp. (Nasdaq:EXAS) today announced its financial results for the quarter ended Sept. 30, 2014.
EXAS: 24.07 (-0.74)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 9.62 (+0.01), NLNK: 32.65 (-1.23), ILMN: 192.58 (-0.84), EXAS: 24.07 (-0.74)
After Yesterday's Decline of 3.26%, Exact Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Wed Oct 22, 5:09PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $23.36 to a high of $24.28. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $23.38 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EXAS: 24.07 (-0.74)
MDVIP Is The First Network of Personalized Healthcare Physicians To Offer Cologuard, A New Noninvasive Stool-Based DNA Test For Colon Cancer
Business Wire - Wed Oct 22, 7:03AM CDT
MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard(R), the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through their physicians. MDVIP is the first personalized healthcare network to partner with Exact Sciences to bring this innovative new test to its primary care physicians.
EXAS: 24.07 (-0.74)
Exact Sciences Announces MDVIP As The First Network of Personalized Healthcare Physicians To Offer Cologuard, A New Noninvasive Stool-Based DNA Test For Colon Cancer
Business Wire - Wed Oct 22, 7:01AM CDT
MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard(R), the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through their physicians. MDVIP is the first personalized healthcare network to partner with Exact Sciences to bring this innovative new test to its primary care physicians.
EXAS: 24.07 (-0.74)
Affymetrix-Ariosa Ink Supply Deal for Harmony Prenatal Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:55PM CDT
Affymetrix Inc. (AFFX) announced that it has entered a multi-year supply agreement with San Jose, California-based Ariosa Diagnostics, Inc.
EBS: 22.62 (+0.27), FCSC: 2.80 (-0.05), EXAS: 24.07 (-0.74), AFFX: 9.01 (+0.71)
Exact Sciences to Host Third-Quarter 2014 Results Webcast and Call
Business Wire - Mon Oct 20, 3:30PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss its third-quarter 2014 financial results on Oct. 27, 2014.
EXAS: 24.07 (-0.74)
Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 8:39AM CDT
Regeneron Pharmaceuticals, Inc. (REGN) was a big mover last session, as its shares rose nearly 9% on the day.
MACK: 9.17 (-0.11), HALO: 9.62 (+0.01), EXAS: 24.07 (-0.74), REGN: 393.72 (+0.92)
Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 9.17 (-0.11), HALO: 9.62 (+0.01), EBS: 22.62 (+0.27), EXAS: 24.07 (-0.74)
CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business Talk Radio -- October 16, 2014
Marketwired - Wed Oct 15, 1:25PM CDT
"The Traders Network Show" broadcasted daily on Clear Channel -- iHeart Radio DFW1190AM KFXR, is pleased to announce Exact Sciences (NASDAQ: EXAS) CEO Kevin T. Conroy will be interviewed live on Thursday, Oct 16th, at 7:30am EDT by host Michael Yorba streamed globally on iHeart Radio. Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
EXAS: 24.07 (-0.74)
Can the Rally in EXACT Sciences (EXAS) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:21AM CDT
Can the Rally in EXACT Sciences (EXAS) Shares Continue?
EXAS: 24.07 (-0.74)
Exact Sciences (EXAS) Looks Strong: Stock Surges 35.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:44AM CDT
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares surge a massive 36% on the day
EBS: 22.62 (+0.27), CYCC: 3.23 (-0.11), FCSC: 2.80 (-0.05), EXAS: 24.07 (-0.74)
'Fast Money' Recap: Is the S&P 500 Ready to Rebound Now?
at The Street - Sat Oct 11, 4:00AM CDT
The trading panel discussed what must happen to get investors back into the markets.
DRIV: 25.57 (+0.18), MU: 33.09 (+1.27), GD: 139.76 (+1.47), BUD: 110.98 (+0.97), GS: 189.99 (+3.02), SYNA: 68.43 (+2.97), CUDA: 32.15 (+1.99), JCP: 7.61 (-0.02), PLAY: 19.66 (+0.28), EXAS: 24.07 (-0.74), SOXX: 87.15 (+3.28), INTC: 34.01 (+1.43), SO: 46.36 (-0.09), SNDK: 94.14 (+3.83), MS: 34.95 (+0.43)
Exact Sciences up on test
at Investor's Business Daily - Fri Oct 10, 5:33PM CDT
Shares of Exact Sciences (EXAS) surged more than 45% to a new high before settling down, following news that the Center for Medicare and Medicaid Services agreed with the biotech's reimbursement rate of $502 per test of Cologuard, the 1st noninvasive...
EXAS: 24.07 (-0.74)
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 35.76% Rise
Comtex SmarTrend(R) - Fri Oct 10, 4:55PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $23.55 to a high of $26.79. Yesterday, the shares gained 35.8%, which took the trading range above the 3-day high of $18.89 on volume of 17.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 24.07 (-0.74)
Exact Sciences soars on colon cancer test ruling
By The Associated Press - AP - Fri Oct 10, 4:11PM CDT
Shares of Exact Sciences soared to an all-time high Friday after the company said its new colon cancer test will be covered by Medicare.
EXAS: 24.07 (-0.74)
Tesla and PepsiCo are big market movers
AP - Fri Oct 10, 3:27PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
PGR: 26.41 (+0.42), TSLA: 241.70 (+3.04), COST: 133.37 (+0.37), EXAS: 24.07 (-0.74), VTR: 68.51 (+0.52), SYMC: 24.82 (-0.03), PEP: 96.17 (+0.52)
Exact Sciences Announces Meriter-UnityPoint Health Now Offering Cologuard(R)
Business Wire - Wed Oct 29, 8:00AM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that Meriter-UnityPoint Health will now offer Cologuard(R), the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer.
EXAS: 24.07 (-0.74)
Downgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Tue Oct 28, 7:04AM CDT
Exact Sciences (NASDAQ:EXAS) was downgraded from Overweight to Equal Weight at Stephens today. The stock closed yesterday at $23.61 on volume of 2.4 million shares, below average daily volume of 2.5 million. Exact Sciences (NASDAQ:EXAS) is currently priced 20.7% above its average consensus analyst price target of $18.73. The stock should discover initial support at its 50-day moving average (MA) of $20.89 and subsequent support at its 200-day MA of $15.94.
EXAS: 24.07 (-0.74)
Exact Sciences misses 3Q profit forecasts
Automated Insights - Mon Oct 27, 6:36AM CDT
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Monday reported a third-quarter loss of $32.1 million.
EXAS: 24.07 (-0.74)
Exact Sciences Reports Third-Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 6:30AM CDT
Exact Sciences Corp. (Nasdaq:EXAS) today announced its financial results for the quarter ended Sept. 30, 2014.
EXAS: 24.07 (-0.74)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 9.62 (+0.01), NLNK: 32.65 (-1.23), ILMN: 192.58 (-0.84), EXAS: 24.07 (-0.74)
After Yesterday's Decline of 3.26%, Exact Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Wed Oct 22, 5:09PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $23.36 to a high of $24.28. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $23.38 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EXAS: 24.07 (-0.74)
MDVIP Is The First Network of Personalized Healthcare Physicians To Offer Cologuard, A New Noninvasive Stool-Based DNA Test For Colon Cancer
Business Wire - Wed Oct 22, 7:03AM CDT
MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard(R), the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through their physicians. MDVIP is the first personalized healthcare network to partner with Exact Sciences to bring this innovative new test to its primary care physicians.
EXAS: 24.07 (-0.74)
Exact Sciences Announces MDVIP As The First Network of Personalized Healthcare Physicians To Offer Cologuard, A New Noninvasive Stool-Based DNA Test For Colon Cancer
Business Wire - Wed Oct 22, 7:01AM CDT
MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard(R), the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through their physicians. MDVIP is the first personalized healthcare network to partner with Exact Sciences to bring this innovative new test to its primary care physicians.
EXAS: 24.07 (-0.74)
Affymetrix-Ariosa Ink Supply Deal for Harmony Prenatal Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:55PM CDT
Affymetrix Inc. (AFFX) announced that it has entered a multi-year supply agreement with San Jose, California-based Ariosa Diagnostics, Inc.
EBS: 22.62 (+0.27), FCSC: 2.80 (-0.05), EXAS: 24.07 (-0.74), AFFX: 9.01 (+0.71)
Exact Sciences to Host Third-Quarter 2014 Results Webcast and Call
Business Wire - Mon Oct 20, 3:30PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss its third-quarter 2014 financial results on Oct. 27, 2014.
EXAS: 24.07 (-0.74)
Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 8:39AM CDT
Regeneron Pharmaceuticals, Inc. (REGN) was a big mover last session, as its shares rose nearly 9% on the day.
MACK: 9.17 (-0.11), HALO: 9.62 (+0.01), EXAS: 24.07 (-0.74), REGN: 393.72 (+0.92)
Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 9.17 (-0.11), HALO: 9.62 (+0.01), EBS: 22.62 (+0.27), EXAS: 24.07 (-0.74)
CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business Talk Radio -- October 16, 2014
Marketwired - Wed Oct 15, 1:25PM CDT
"The Traders Network Show" broadcasted daily on Clear Channel -- iHeart Radio DFW1190AM KFXR, is pleased to announce Exact Sciences (NASDAQ: EXAS) CEO Kevin T. Conroy will be interviewed live on Thursday, Oct 16th, at 7:30am EDT by host Michael Yorba streamed globally on iHeart Radio. Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
EXAS: 24.07 (-0.74)
Can the Rally in EXACT Sciences (EXAS) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:21AM CDT
Can the Rally in EXACT Sciences (EXAS) Shares Continue?
EXAS: 24.07 (-0.74)
Exact Sciences (EXAS) Looks Strong: Stock Surges 35.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:44AM CDT
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares surge a massive 36% on the day
EBS: 22.62 (+0.27), CYCC: 3.23 (-0.11), FCSC: 2.80 (-0.05), EXAS: 24.07 (-0.74)
'Fast Money' Recap: Is the S&P 500 Ready to Rebound Now?
at The Street - Sat Oct 11, 4:00AM CDT
The trading panel discussed what must happen to get investors back into the markets.
DRIV: 25.57 (+0.18), MU: 33.09 (+1.27), GD: 139.76 (+1.47), BUD: 110.98 (+0.97), GS: 189.99 (+3.02), SYNA: 68.43 (+2.97), CUDA: 32.15 (+1.99), JCP: 7.61 (-0.02), PLAY: 19.66 (+0.28), EXAS: 24.07 (-0.74), SOXX: 87.15 (+3.28), INTC: 34.01 (+1.43), SO: 46.36 (-0.09), SNDK: 94.14 (+3.83), MS: 34.95 (+0.43)
Exact Sciences up on test
at Investor's Business Daily - Fri Oct 10, 5:33PM CDT
Shares of Exact Sciences (EXAS) surged more than 45% to a new high before settling down, following news that the Center for Medicare and Medicaid Services agreed with the biotech's reimbursement rate of $502 per test of Cologuard, the 1st noninvasive...
EXAS: 24.07 (-0.74)
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 35.76% Rise
Comtex SmarTrend(R) - Fri Oct 10, 4:55PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $23.55 to a high of $26.79. Yesterday, the shares gained 35.8%, which took the trading range above the 3-day high of $18.89 on volume of 17.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 24.07 (-0.74)
Exact Sciences soars on colon cancer test ruling
By The Associated Press - AP - Fri Oct 10, 4:11PM CDT
Shares of Exact Sciences soared to an all-time high Friday after the company said its new colon cancer test will be covered by Medicare.
EXAS: 24.07 (-0.74)
Tesla and PepsiCo are big market movers
AP - Fri Oct 10, 3:27PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
PGR: 26.41 (+0.42), TSLA: 241.70 (+3.04), COST: 133.37 (+0.37), EXAS: 24.07 (-0.74), VTR: 68.51 (+0.52), SYMC: 24.82 (-0.03), PEP: 96.17 (+0.52)
